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Drugs frequently require interactions with multiple
targets—via a process known as polypharmacol-
ogy—to achieve their therapeutic actions. Currently,
drugs targeting several serotonin receptors, including
the 5-HT2C receptor, are useful for treating obesity,
drug abuse, and schizophrenia. The competing
challenges of developing selective 5-HT2C receptor
ligands or creating drugs with a defined polypharma-
cological profile, especially aimed at G protein-
coupled receptors (GPCRs), remain extremely diffi-
cult. Here, we solved two structures of the 5-HT2C
receptor in complex with the highly promiscuous
agonist ergotamine and the 5-HT2A-C receptor-selec-
tive inverse agonist ritanserin at resolutions of 3.0 Å
and 2.7 Å, respectively. We analyzed their respective
binding poses to provide mechanistic insights into
their receptor recognition and opposing pharmaco-
logical actions. This study investigates the structural
basis of polypharmacology at canonical GPCRs
and illustrates how understanding characteristic
patterns of ligand-receptor interaction and acti-
vationmay ultimately facilitate drug design atmultiple
GPCRs.INTRODUCTION
For effective G protein-coupled receptor (GPCR) drug discov-
ery, some degree of receptor selectivity is essential to avoid
deleterious ‘‘off-target’’ interactions with related GPCRs and
other druggable targets (e.g., ion channels, kinases, enzymes,
and so on) (Elkins et al., 2016). As GPCRs frequently have
conserved orthosteric binding pockets, drugs targeting these
sites often interact with multiple molecular targets; the pro-
cess whereby drugs bind to many targets is known as
polypharmacology.
Indeed, creating effective medications which are selective
(e.g., ‘‘magic bullets’’) is not only difficult but also frequently
unsuccessful, particularly for complex CNS disorders where
the etiologies may be multifactorial and polygenic (Boyle
et al., 2017). In fact, drugs with a polypharmacological basis
(e.g., ‘‘magic shotguns’’) are frequently more effective thera-
peutics (Roth et al., 2004), as exemplified by the atypical anti-
psychotics clozapine (Clozaril) and aripiprazole (Abilify), which
interact with numerous GPCRs (Jacobson et al., 2014; McCorvy
and Roth, 2015; Roth et al., 2004; Shapiro et al., 2003). Addi-
tionally, carazolol and tiotropium exert their therapeutic effects
by interacting with multiple adrenergic (Cherezov et al., 2007;
Moukhametzianov et al., 2011) and muscarinic acetylcholine re-
ceptors (Kruse et al., 2012; Thal et al., 2016), respectively. The
rational design of drugs that simultaneously interact with multi-
ple GPCRs, therefore, has the potential to yield medications
with improved efficacy for complex disorders (Besnard 
et al., 2012).
Structure-based drug design approaches have facilitated the 
creation of selective GPCR drugs (Wang et al., 2017) with 
improved therapeutic profiles, as exemplified by the recent 
discovery of m-opioid selective G protein-biased agonists (Man-
glik et al., 2016). Structure-guided approaches, perforce, require 
high-resolution crystal structures in order to exploit ligand-bind-
ing pocket interactions at the targeted GPCR (Wacker et al., 
2017a; Wang et al., 2017). However, structure-guided drug 
design will not typically predict a compound’s off-target actions. 
Ultimately, structure-based polypharmacological drug design 
will require many high-resolution GPCR structures with various 
chemotypes to illuminate how polypharmacology might be 
achieved at multiple defined drug targets.
The 5-HT2C serotonin receptor (5-HT2C) is a validated target 
for anti-obesity medications as illustrated by the selective
5-HT2C agonist lorcaserin (Belviq). The 5-HT2C is also a potential 
therapeutic target for depression, schizophrenia, drug addiction, 
and other disorders (McCorvy and Roth, 2015; Palacios et al., 
2017; Pogorelov et al., 2017). Creating selective 5-HT2C agonists 
is extremely challenging, however, as off-target agonist activity 
at the closely related 5-HT2A and 5-HT2B receptors leads to 
lysergic acid diethylamide (LSD)-like hallucinations (Nichols, 
2016) and cardiac valvulopathy (Roth, 2007), respectively. More-
over, the 5-HT2C exhibits several RNA-edited isoforms, where 
the non-edited isoform (INI) displays high constitutive activity 
that can be exploited to quantify an inverse agonist’s activity 
(Barker et al., 1994).
To date, only two serotonin receptor structures have been 
solved: the 5-HT1B and the 5-HT2B, both in complex with ergot-
amine (ERG) (Wacker et al., 2013, 2017b; Wang et al., 2013) and, 
most recently, 5-HT2B in complex with LSD (Wacker et al., 
2017b). ERG is a naturally occurring ergot anti-migraine drug 
that contains an ergoline nucleus, a common chemotype for 
many drugs including LSD, bromocriptine, methysergide, and 
lisuride. ERG, however, has a complex polypharmacological 
profile with serious side effects, including cardiac valvulopathy 
via 5-HT2B serotonin receptor agonism, which limits its wide-
spread use as an anti-migraine medication. In contrast, ritanserin 
(RIT) is a selective 5-HT2 receptor inverse agonist that has been 
previously investigated as an adjunct for antipsychotic medica-
tions (Den Boer et al., 2000). RIT contains a 4-benzylidenepiper-
idine core scaffold, which is also found in the promiscuous 
antipsychotic clozapine. The 4-benzylidenepiperidine is a known 
privileged scaffold with applications for exploiting multiple 
GPCRs to yield a desired polypharmacological profile (Garland 
and Gloriam, 2011).
Here, we present the structures of the 5-HT2C INI isoform in 
complex with both the polypharmacological agonist ERG and 
the selective inverse agonist RIT in order to clarify the struc-
tural features responsible for GPCR polypharmacology. To this 
end, we reveal the active-like state 5-HT2C receptor structure 
with ERG and, for comparison, an inactive state with RIT. 
Knowledge of these crystal structures will facilitate the basis of 
chemotype-specific recognition, inverse agonism, and 
receptor activation and will enable polypharmacological drug 
design.RESULTS
Overall Structure of Agonist- and Inverse-Agonist-
Bound 5-HT2C
The human 5-HT2C was crystallized with a thermostabilized
apocytochrome b562RIL (BRIL) fused to the third intracellular
loop (IL3) and a single C360N7.45 thermostabilizing mutation
(superscripts denote amino acid position as described by Balles-
teros and Weinstein, 1995) (Figure S1). In both structures, ERG
and RIT are bound in the presumed orthosteric site and also
engage a potential extended binding site encompassing the
extracellular portions of transmembrane (TM) helices III, V, VI,
and VII as well as extracellular loop 2 (EL2) (Figure 1A). Although
disordered in other solved serotonin receptor crystal structures
(Liu et al., 2013; Wacker et al., 2013, 2017b; Wang et al.,
2013), all extracellular loops are well resolved in both 5-HT2C
crystal structures. Superposition of the ERG and RIT complexes
shows shifts of 7.0 Å, 3.9 Å, and 6.6 Å at the intracellular ends of
helices VI, V, and III, respectively, indicating that they represent
different conformational states of the receptor (Figure 1B).
Compared to the active and inactive state structures of
b2-adrenergic receptor (b2AR) (Rasmussen et al., 2011; Wacker
et al., 2010), 5-HT2C-RIT resembles the inactive state conforma-
tion of b2AR, whereas 5-HT2C-ERG shows all ‘‘active-like
features’’ exemplified by the active state of b2AR (Figure S2).
Superposition of the 5-HT1B, 2B, 2C-ERG and 5-HT2C-RIT
(Wacker et al., 2013; Wang et al., 2013) structures shows an
increased opening on the intracellular ends of helices V and VI
in the order 5-HT2B-ERG < 5-HT1B-ERG < 5-HT2C-ERG
compared to 5-HT2C-RIT (Figures 1C and S2).
Different Binding Modes of ERG and RIT
ERG and RIT have different chemical scaffolds with distinct
5-HT2C activity: ERG acts as an agonist, whereas RIT is an in-
verse agonist for both Gaq-inositol phosphate accumulation
and b-arrestin2 recruitment (Figure S3). These differential effi-
cacies are mirrored by their distinctive binding modes as
observed in the 5-HT2C crystal structures, where the only com-
mon interaction is the salt bridge between the protonated nitro-
gen of the ligand and the conserved aspartate, D1343.32—a
canonical interaction for aminergic and many other GPCRs (Fig-
ure 2A). Compared to the ERG-bound structure, RIT binds
approximately one helical turn deeper into the TM bundle (Fig-
ure 2B), which is outside of the recognized orthosteric site of
other solved aminergic GPCR structures (Venkatakrishnan
et al., 2013). By contrast, ERG’s shallower binding pose allows
an aromatic interaction only with F3286.52 and van der Waals
(vdW) contact with W3246.48 (Figures 2B and 2H).
The deep binding pose of RIT in the 5-HT2C is characterized by
one of the 4-fluorophenyl groups encased in a hydrophobic
pocket between helices V and VI, where it interacts via
halogen-aromatic interactions with F2235.47 and F3206.44 and
aromatic edge-to-face p-p stacking interactions with residues
F3286.52 and W3246.48, the purported ‘‘toggle switch’’ important
for GPCR activation (Figures 2B and 2G) (Preininger et al., 2013).
We validated RIT’s binding pose by mutating W3246.48, F2235.47
and F3206.44, all of which decreased RIT’s affinity (Figures 2E
and 2F; Table S2). The W324L6.48 mutation especially reduced
Figure 1. Overall Architecture of 5-HT2C-ERG and -RIT and Their Comparison with 5-HT1B,2B-ERG
(A) ERG- (agonist) and RIT- (inverse agonist) bound 5-HT2C are shown as orange and green cartoons. ERG and RIT are shown as orange and green balls and
sticks, respectively. The helices are indicted with I through VIII.
(B) The top panel is the extracellular view. The bottom panel is the intracellular view (loops are omitted for clarity). The arrows show helical shifts as indicated
(distance measured by the Ca atoms of I303
6.27, A2455.69, and R1573.55) between the 5-HT2C-ERG and 5-HT2C-RIT structures.
(C) Superposition of the following structures: 5-HT2C-ERG (orange), 5-HT2C-RIT (green), 5-HT1B-ERG (light blue; PDB: 4IAR), and 5-HT2B-ERG (yellow;
PDB: 4IB4).
See also Figures S1 and S2 and Table S1.RIT affinity by >1,000-fold, whereas W324F6.48 and W324Y6.48
mutations, which preserve the aromatic character of this residue,
had substantially less effects on RIT binding affinity (Figure 2E;
Table S2). Thesemutations support the hypothesis that the 4-flu-
orophenyl moiety is dependent on p-p stacking interactions
below the commonly recognized aminergic orthosteric site and
that these interactions with W3246.48 are apparently driving
RIT’s deep binding pose.
The second 4-fluorophenyl group of RIT occupies essentially
the same site as the indole of ERG and is lined by V1353.33,
T1393.37, V1854.56, S2195.43, A2225.46, and F3276.51 (Figure 2D),
with the aromatic ring systems positioned orthogonally to one
another in the binding pocket (Figures 2A and 2D). The second
4-fluorophenyl groupalso apparently ‘‘pushes’’ against theback-
bone of helix V at residue G2185.42 (Figure 2D). Mutation of this
residue to G218A5.42 attenuates RITs binding affinity more than
10-fold (Figure 2F) but only has a modest effect on ERG affinity,
further supporting the differential binding poses (Table S2).
The thiazolopyrimidine of RIT, which stems from the charged
nitrogen of the 4-benzylidenepiperidine core scaffold, is located
orthogonally to the ergoline ring in the 5-HT2C-ERG structure and
is positioned toward helices II and VII interacting with Y118EL1,
V208EL2, F3276.51, N3517.36 and V3547.39 (Figure 2C). The
ligand contacts at EL2 also differ between the 5-HT2C-RIT and
5-HT2C-ERG structures as RIT has only hydrophobic vdW con-
tacts, but ERG engages in a hydrogen bond with the backbone
of L209EL2 (Figure 2C). Finally, ERG’s terminal benzyl moiety ex-tends much further toward the extracellular loops of the receptor
than RIT making vdW contacts with residues L209 in EL2 and
V2155.39, S3346.58, and V3356.59 at the topmost turns of helices
V and VI (Figure 2H).
Conformational Changes between Agonist- and Inverse
Agonist-Bound 5-HT2C
Comparison of the 5-HT2C-ERG and 5-HT2C-RIT crystal struc-
tures also provides key insights into activation-related confor-
mational changes in 5-HT2C. Importantly, the intracellular end
of the helix VI in 5-HT2C-ERG is tilted outward by 7.0 Å and helix
III is shifted inward by 6.6 Å compared to the 5-HT2C-RIT struc-
ture (Figure 1B, bottom panel). Hydrogen bonds between the
highly conserved D1343.32 and Y3587.43 are observed in both
structures (Figure 3A). A comparison of the structures reveals
an overall 1–2 Å binding pocket compaction with inward shift
of helices V, VI, and VII around the ergoline moiety of ERG (Fig-
ure 1B, top panel). Such compaction of the binding pocket is
expected for ergolines and the endogenous agonist 5-hydroxy-
tryptamine (5-HT) (Wang et al., 2013), both of which are less
bulky than the 4-(diphenylmethylene)-piperidine core of the
inverse agonist RIT. These helix movements are accompanied
by rotamer switches in the conserved P5.50-I3.40-F6.44 (P-I-F)
motif and a shift of the W3246.48 ‘‘toggle switch’’ in helix VI (Fig-
ure 3B), representative of active-state-like structures at biogenic
amine and other GPCRs (Venkatakrishnan et al., 2013; Wacker
et al., 2013). As mentioned above, the inverse agonist RIT binds
Figure 2. Different Binding Modes of ERG and RIT in 5-HT2C
(A–D) Superposition of the 5-HT2C-ERG (orange) and RIT (green) ligand binding pockets with an overview and close-up views of the orthosteric and extended
binding sites. (A) Overall distinctive bindingmodes of ERG and RIT observed in 5-HT2C. (B) The deeper binding pose of RIT and shallower binding pose of ERG. (C)
Key interactions around RIT’s thiazolopyrimidine as well as ERG’s ergoline ring and terminal benzyl moiety. (D) The second 4-fluorophenyl group of RIT occupies
the same site as the indole of ERG and positions orthogonally to each another in the binding pocket.
(E) W3246.48 appears to be a major determinant of RIT’s binding mode as measured by binding affinity loss at mutations. Binding affinity is partially recovered by
the conservative mutation W324F6.48.
(F) Mutations of residues F2235.47, F3206.44, and G2185.42 also show RIT affinity loss, but less compared to W3246.48.
(G and H) Schematic representation of RIT (G) and ERG (H) contacts with the 5-HT2C, respectively. Lines indicate interactions types: orange, polar, salt bridges,
and hydrogen bonds; blue, aromatic contacts; and green, dipolar interactions.
Data represent mean ± SEM of three independent experiments performed in duplicate (E and F).
See also Tables S2 and S7.
Figure 3. Conformational Changes between 5-HT2C-ERG and -RIT Structures and Mutagenesis Validation
(A) ERG (orange sticks) and RIT (green sticks) in the binding pocket of 5-HT2C. Key residues in 5-HT2C-ERG and 5-HT2C-RIT are shown in orange and green sticks,
respectively. Hydrogen bonds between D1343.32 and Y3587.43 are shown by the dashed line.
(B) Conformational changes of I1423.40 and F3206.44 in the P-I-F motif and the W3246.48 ‘‘toggle switch’’ in helix VI.
(C) Mutations of W3246.48 and F3206.44 completely abolish RIT’s Gaq inverse agonism, yet retain b-arrestin2 inverse agonism. Mutations of I142
3.40 selectively
abolish RIT’s Gaq inverse agonism and instead show weak agonism.
Data represent mean ± SEM from three independent experiments performed in triplicate.
See also Figure S3 and Table S7.deeper than most class A GPCR ligands in the TM helical bundle
where one of its 4-fluorophenyl groups forms tight interaction
withW3246.48, I1423.40, and F3206.44 side chains thus apparently
preventing the conformational changes in these key activation
microswitches. Furthermore, the 4-fluorophenyl group of RIT is
in close proximity to I1423.40 apparently facilitating an outward
shift of the intracellular end of helix III (Figure 1B, bottom panel),
which potentially explains the inverse agonist activity of RIT at
this receptor isoform.
To test this hypothesis, functional studieswere performedwith
mutants of these key microswitch residues in 5-HT2C measuring
Gaq activation and b-arrestin2 recruitment. Mutations of the
‘‘toggle switch’’ W3246.48 and F3206.44, which are part of the
P-I-F trigger motif, selectively abolish RIT’s Gaq inverse agonism
without affecting RIT’s b-arrestin2 inverse agonist activity (Fig-
ure 3C) indicating that these microswitch residues are mainly
involved in the Gaq activation process. Furthermore, the
I142A3.40 mutation of the P-I-F motif also selectively abolishesRIT’s Gaq inverse agonism and the I142F
3.40 mutant transforms
RIT into a Gaq partial agonist with little agonist effect on arrestin
recruitment (Figure 3C). This mutant I142F3.40 likely imparts
additional aromatic stacking properties to RIT, indicating that
the P-I-F motif is important for RIT’s inverse agonist profile (Fig-
ure 3C). These results support a model whereby the 4-fluoro-
phenyl moiety of RIT stabilizes an inactive state of the receptor
via interference with the ‘‘toggle switch’’ W6.48 and ‘‘trigger
motif’’ P5.50-I3.40-F6.44 and that these microswitch residues are
critical for inverse agonist activity and the Gaq activation
process, in general, at the 5-HT2C.
Multiple ERG-Serotonin Receptor Structure Complexes
Reveal Determinants of Polypharmacology
To illuminate ERG’s polypharmacology, we first assessed its
binding affinity across the aminergic receptor family. ERG shows
appreciable affinity (Ki < 10 mM) for nearly 70% of all human ami-
nergic GPCRs with low or sub-nanomolar affinity for fifteen of
those receptors (Table S3). Further characterization of ERG 
activity revealed a diverse functional profile of either G protein 
agonist activity or b-arrestin2 recruitment activity, or in some 
cases both (Figure S4), indicating that ERG possesses functional 
selectivity across the aminergic GPCRome. However, ERG 
possessed no apparent G protein-dependent agonist activity 
at the D3 dopamine, a1B, a1D or b2 adrenergic receptors despite 
appreciable affinity indicating antagonism at these receptors. 
Interestingly, ERG was an inverse agonist at 5-HT7 where inverse 
agonism has been previously reported for the structurally related 
ergoline analog LSD (Wacker et al., 2013). To fully illuminate 
ERG’s polypharmacological profile, ERG was then screened at 
320 non-olfactory human GPCRs via a b-arrestin2 recruitment 
assay (Kroeze et al., 2015), which unexpectedly revealed 
apparent opioid receptor agonist activity (Figure S5; Table S4).
To uncover the molecular basis for ERG’s high affinity and 
polypharmacological profile at aminergic GPCRs, we analyzed 
the binding modes of ERG at the 5-HT1B, 2B, 2C-ERG crystal 
structure complexes (Wacker et al., 2013; Wang et al., 2013). 
ERG shares a common binding mode at all three of these recep-
tors, where the only difference is the orientation of the benzyl 
substituent in 5-HT1B-ERG complex (Figure 1C). In regions in 
which ERG packs most tightly and has polar interactions—
around the ergoline scaffold—all receptors demonstrating high 
ERG affinity exhibit highly conserved residue properties (Figures 
4A and 4B, left panel). The ergoline core is surrounded by four 
helices where helices III and VI sandwich the planar sides of 
the ergoline core, whereas the other two edges are enclosed 
by helices V and VII. In addition to D3.32, which forms a salt 
bridge to most aminergic ligands, positions 3.33, 3.36, 3.37, 
5.42, and 5.46 are in very close contact with ERG in all three 
structures and are not able to accommodate significant ERG 
affinity when there are significantly larger amino acids present 
at these residue positions. Additionally, the conserved T3.37 
residue and semi-conserved A/S/T5.46 residues form either 
vdW interactions and/or a hydrogen bond to ERG’s indole 
N-H. Three additional helix VI positions (6.48, 6.51, and 6.52) 
contribute favorable vdW and aromatic interactions where 
alanine or leucine mutations of these residues only lead to 
reduced but not abrogated ERG binding at 5-HT2C (Table S2) 
and 5-HT1B, 2B (Wang et al., 2013). Therefore, the ergoline core 
is recognized by nine key residues, eight of which have specific 
conserved amino acid properties to enable binding. All of these 
properties are present in all receptors that demonstrate high 
ERG affinity (Figures 4A and 4B, left panel).
For ERG’s cyclic tripeptide and benzyl substituents, the struc-
tures display only non-specific side-chain vdW contacts, which 
tolerate a high degree of flexibility and diversity of amino acids. 
One exception to this is the conservation of a position in EL2 
(L209 in 5-HT2C) of all receptors demonstrating high ERG affinity, 
where a small aliphatic residue such as a leucine, valine, or 
isoleucine is almost always present. Interestingly, the homolo-
gous EL2 residue found in 5-HT2B (L209EL2) and in 5-HT2A 
(L229EL2) has been recently studied as a determinant for ligand 
residence time, which contributes to b-arrestin recruitment 
(Wacker et al., 2017b). Similarly observed in the 5-HT2C struc-
ture, the side chain of L209EL2 residue points into a cavity formed 
by the bent tripeptide moiety of ERG and the space of the cavityis ideal for smaller aliphatic residues such as leucine, valine, or
isoleucine (Figures 4A and 4B), likely contributing to ERG’s
shared binding pose among GPCRs.
RIT Structure Reveals Determinants of 5-HT2 Subtype
Selectivity
Although RIT is selective for 5-HT2-family receptors, it contains a
4-benzylidenepiperidine moiety, which is a variant of a known
4-arylpiperidine GPCR privileged structure (Garland and Glo-
riam, 2011) (Figure 5A). The 5-HT2C-RIT crystal structure reveals
that D3.32, W6.48, and at least one aromatic residue at positions
5.47 and/or 6.52 are important for binding of this privileged struc-
ture. Within class A GPCRs, this sub-site is conserved in most
aminergic receptors, all four opioid receptors and the melanin-
concentrating hormone receptor 1 (MCR1) (Figure 5B). Like the
ergoline scaffold of ERG, the 4-benzylidenepiperidine privileged
structure found in RIT ensures binding to a wide range of recep-
tors thereby providing a molecular basis for use of this privileged
structure as a starting point for polypharmacological design.
Indeed, this is nicely illustrated by the polypharmacology of
clozapine binding to nearly thirty aminergic receptors (Roth
et al., 2004; Yadav et al., 2011a) and by cinnarizine binding to
fifteen different aminergic receptors and the m-opioid receptor
(Figure 5C). By contrast, RIT binds almost exclusively to 5-HT2
receptors with >100-fold preference over any other tested
GPCR with the exception of the H2 histamine receptor
(19-fold) (Figure 6A; Table S3).
To uncover themolecular basis for RIT’s 5-HT2 receptor selec-
tivity, despite containing the embedded promiscuous 4-benzyli-
denepiperidine privileged structure, we identified residues
responsible for RIT’s selectivity and designed a series of muta-
tions. We exchanged the differing binding site residues in
5-HT2C with those of 5-HT1A that demonstrated low affinity for
RIT (Figure 6A). The most pronounced effects occurred for the
two mutants G218S5.42 (60-fold) and V354N7.39 (425-fold), both
of which are unique to 5-HT2A-C subtypes (Figure 6B; Table
S5). In accordance with the structure showing only non-specific
interactions, the other mutations, e.g., S138C3.36, showed small
or negligible effect on RIT affinity. As previously mentioned,
G2185.42 and V3547.39 engage the second 4-fluorophenyl of
RIT and the thiazolopyrimidine, both of which are structural mod-
ifications stemming from the 4-benzylidenepiperidine core
scaffold that are unique to RIT (Figure 6C). Furthermore, the
importance for residues 5.42 and 7.39 conferring 5-HT2 selec-
tivity is supported by the fact that 5-HT1A, which contains
S5.42 and N7.39 at these positions, has a 1,300-fold lower af-
finity for RIT than does 5-HT2C but sub-nanomolar affinity for
ERG (Table S3). In fact, 5-HT4, which does not demonstrate
any appreciable RIT affinity at all, contains larger residues at
both 5.42 and 7.39 positions (Cys and Leu, respectively). To
confirm the notion that residues 5.42 and 7.39 are more impor-
tant for driving RIT subtype selectivity rather than ligand promis-
cuity, we also sought to test clozapine at these mutations, which
also contains an embedded 4-benzylidenepiperidine privileged
structure. Interestingly, clozapine is only modestly affected
(4-fold or below) by any of the tested binding site mutants
(Table S5). These results clarify that RIT’s 4-fluorophenyl
and thiazolopyrimidine interactions with respective residues
Figure 4. Polypharmacological Profile of ERG
(A) The chemical structure of ERG highlighting the ergoline core (brown), tripeptide (blue), and benzyl portions (purple) in the structures of 5-HT2C (orange), 5-HT1B
(light blue; PDB: 4IAR), and 5-HT2B (yellow; PDB: 4IB4). ERG is shown as thick sticks, and the protein backbone is represented as a cartoon and the side chains of
relevant amino acids as thin sticks. For clarity, the Ca-carbon of G5.42 is depicted as a small sphere.
(B) Mean values of ERG affinities (Ki) in nanomolars from radioligand competition binding assays represent the mean from experiments performed in duplicate
(see also Table S3). Sequence alignments of the three subsites: gray background, conservation of positions and residue types critical for ERG binding; SN, short
and negative; IH, intermediate length and hydrophobic; SU, small and unbranched; VSP, very small or small and polar; HF, hydrophobic with a maximum size of
Phe; HA, hydrophobic and aliphatic. Receptors are listed in order of decreasing ERG affinity (Ki color scale green over white to orange) but separated into
aminergic and non-aminergic receptors.
See also Figures S4 and S5 and Tables S3 and S4.G2185.42 and V3547.39, which are residues exclusive to 5-HT2 re-
ceptors, are primary determinants of RIT’s 5-HT2 selectivity.
DISCUSSION
Here, we determined agonist- and antagonist-stabilized struc-
tures of the 5-HT2C receptor, a molecular target important fordrugs that can treat diseasesasdiverse asobesity, schizophrenia,
and drug abuse. Importantly, the 5-HT2C-ERGand -RIT structures
not only reveal the molecular determinants for selective ligand
binding across GPCRs but also reveal a structural basis for
promiscuous ligand ergotamine binding across several receptor
subtypes (e.g., serotonin, dopamine, adrenergic, histamine,
muscarinic, and opioid). We anticipate that our findings will
Figure 5. Polypharmacology of the 4-Benzylidenepiperidine Privileged Structure
(A) The interactions between the 4-benzylidenepiperidine of RIT and its surrounding residues in the 5-HT2C-RIT structure.
(B) Sequence alignments of the privileged structure subsites with the number of ligands identified in a search for GPCR ligands in ChEMBL containing the
privileged structure and Ki < 1 mM. Conservation of positions critical for binding is shown in a gray background, and conservation is assessed by the residue
properties crucial for interaction; 1AR, aromatic residue in at least one of the two positions.
(C) Examples of ligands identified in the search with confirmedGPCR targets (Ki < 1 mM) are listed, and the privileged structure is highlighted in red in the chemical
structures. For cinnarizine and clozapine, the hits from ChEMBL (Bento et al., 2014) have been supplemented with hits from the PDSP Ki database (Yadav
et al., 2011a).ultimately prove fundamental for not only the design of 
selective 5-HT2C ligands, such as lorcaserin (Belviq), which, 
similar to RIT, has G2185.42 as a major selectivity determinant 
(Figure S6; TableS6), but also will provide a primer for understanding how drugs
like clozapine interact with multiple targets, ultimately facilitating
a structure-guidedpolypharmacological approach todrugdesign.
Figure 6. Ritanserin’s Selectivity on 5-HT2 Receptors
(A) Mean values of RIT affinities (Ki) in nanomolars for radioligand competition binding assays from experiments performed in duplicate. Sequence alignment of
the RIT binding site residues in the eleven serotonin receptors for which RIT’s binding affinity was determined. Conservation of residue type by 5-HT2C is indicated
by a gray background, and mutated positions are indicated with black boxes.
(B) The unique residue types in positions 5.42 and 7.39 of the 5-HT2A-C receptors (see A) appear as major determinants of the RIT selectivity for these receptor
subtypes as binding affinity decreased when mutated in 5-HT2C to the corresponding residues of 5-HT1A, i.e., G218S
5.42 and V354N7.39. Data represent mean ±
SEM of three independent experiments performed in duplicate.
(C) The interactions between RIT and G2185.42 and V3547.39 in the 5-HT2C-RIT structure.
See also Figure S6 and Tables S3 and S5–S7.To unveil the structural basis of GPCRs’ polypharmacology,
we identified ten key conserved amino-acid residues critical for
ERG promiscuity by using sequence alignments of residues
that interact with the ergoline core and benzyl sub-sites at eigh-
teen aminergic receptors that show high ERG affinity (<30 nM). In
fact, deviation from these conserved amino acid types reliably
predicted decreased ERG affinity, dependent on position and
type of amino acid present. To estimate the full target profile of
ERG, we performed a sequence alignment focused on the ten
ERG-interacting residues at all class A GPCRs and found that
ERG’s polypharmacology is not confined to aminergic GPCRs
but also extends to the delta-opioid receptor (d), which has a
semi-conserved binding site and, thus, lower affinity. These ten
conserved amino-acid residues can now be used to guide struc-
ture-based design of polypharmacological ligands at these
receptor types, especially for computational-based methods
that can predict known and unexpected drug targets (Besnard
et al., 2012; Chaudhari et al., 2017). Additionally, we identify
two positions for determining RIT 5-HT2 selectivity, with
V3547.39 having the largest effect on selectivity (425-fold; TableS5), which should be avoided in design of compounds with poly-
pharmacology profiles. This is nicely illustrated by examining
cyproheptadine (Periactin), whose structure is based on the
same 4-(diphenylmethylene)-piperidine core as RIT but lacks
the thiazolopyrimidine (Figure 5C) interacting with V3547.39.
Cyproheptadine displays reduced selectivity between aminergic
receptors (https://pdsp.unc.edu/databases/kidb.php) and
within the 5-HT receptors, e.g., the 5-HT2C versus 5-HT1A selec-
tivity is reduced from 1,288-fold for RIT (Table S3) to 4- to 26-fold
for cyproheptadine (Toll et al., 1998). Taken together, our anal-
ysis of the 5-HT2C-ERG and -RIT structures in comparison with
the previously published 5-HT1B/2B-ERG structures reveal highly
conserved receptor sub-pockets and ligand sub-structures
responsible for GPCR polypharmacology in contrast to the inter-
actions that confer ligand selectivity.
The successful polypharmacological drugs, however, depend
on a diverse range of incorporated pharmacological activity
(e.g., agonism, biased agonism, inverse agonism) at each
respective target. As mentioned, clozapine binds to nearly 30
aminergic receptors at which clozapine mainly demonstrates
antagonist activity (Roth et al., 2004). However, clozapine
has also been shown to demonstrate functional selectivity at
5-HT2A receptor (Yadav et al., 2011b) as well as inverse
agonism at 5-HT7 receptor (Thomas et al., 1998). Therefore,
incorporating functional selectivity or biased agonism into a
drug’s polypharmacological profile can often lead to novel ave-
nues of therapeutic potential, as observed with aripiprazole, a
polypharmacological drug that demonstrates functional selec-
tivity (Shapiro et al., 2003; Tuplin and Holahan, 2017). The
5-HT2C-RIT and the ERG crystal structures shed light on such
a strategy with RIT’s and ERG’s opposing pharmacological
action leading to different activation states of the 5-HT2C. We
identified key areas in both the P-I-F and the W6.48 ‘‘toggle’’
microswitch trigger motifs that appear to be mainly involved
in the 5-HT2C-Gaq activation process and not necessarily
involved in b-arrestin recruitment, which may serve as a starting
point for pathway-selective drugs. In addition, we also show
that RIT interferes with these microswitch motifs to produce
Gaq-dependent inverse agonism, which appears to be an
important mechanism for stabilizing the inactive state of the
receptor. Targeting these motifs may represent a potential
mechanism for the design of novel inverse agonists, especially
aimed at 5-HT2 receptors where current inverse agonists aimed
at this receptor subtype (e.g., pimavanserin) are indicated for
schizophrenia and psychosis-associated with Parkinson’s dis-
ease (Meltzer and Roth, 2013).
It is worth noting that the non-edited INI isoform of the 5-HT2C
was selected to study the ligand-receptor interactions and its
indications to GPCR polypharmacology. There are signaling dif-
ferences among isoforms, and studying other 5-HT2C isoforms
could result in different pharmacological profiles for the specific
receptor subtype. However, because the binding pocket resi-
dues are identical in the edited isoforms, our inferences are not
necessarily isoform specific, and we expect our conclusion con-
cerning polypharmacology and selectivity, which are based on
ligand-receptor binding, to be generally applicable.
Our knowledge of themolecular basis for polypharmacology is
still in its infancy, and it remains difficult to predict what combi-
nation of targets will ultimately lead to more effective treatments
of complex diseases. Evident is the fact that some of the most
successful GPCR drugs (e.g., Clozaril or Abilify for schizo-
phrenia) bind to multiple receptors and that key target combina-
tions ultimately provide the drug’s efficacy. Obtaining a better
understanding of the structural basis for GPCR polypharmacol-
ogy is thus the first step toward a rational utilization of this
principle for future GPCR drug design. Our approach also may
be broadly useful for determining the polypharmacological
determinants of other privileged scaffolds or promiscuous drugs
and provide a roadmap for the rational design of polypharmaco-
logical ligands.STAR+METHODS
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Lines
Spodoptera frugiperda (Sf9) cells were used for 5-HT2C expression and crystallization. Sf9 cells were grown in ESF 921 medium 
(Expression systems) at 27C and 125 rpm. Binding and functional experiments were performed with either Flp-In 293 T-Rex stable 
cell lines (HEK293-derived, female, Invitrogen), HEKT cells (ATCC), tsA201 cells (female, gift from Dr. Penelope S.V. Jones) or HTLA
cells (HEK293-derived, female, gift from Dr. Richard Axel) that express TEV fused-b-arrestin2 and tTA-driven luciferase reporter
(Barnea et al., 2008). HEKT cells were cultured in DMEM containing 10% fetal bovine serum (FBS) and 0.5% Penicillin/Streptomycin.
Flp-IN 293 T-Rex cells were also cultured in DMEM with 10% FBS and 0.5% Penicillin/Streptomycin but also contained selection
antibiotics, 10 mg/mL Blasticidin (Invivogen) and 100 mg/mL Hygromycin B (KSE Scientific). HTLA cells were also cultured in
DMEM with 10% FBS and 0.5% Penicillin/Streptomycin but also contained selection antibiotics, 5 mg/mL Puromycin (Gemini
Bio-Products) and 100 mg/mL Hygromycin B (KSE Scientific). The tsA201 cells were grown and maintained in culture medium
[Dulbecco’s Modified Eagle Medium supplemented with 10% fetal bovine serum, penicillin (100 U/mL) and streptomycin
(100 mg/mL), all from Invitrogen] in a humidified atmosphere at 37C and 5% CO2.
METHOD DETAILS
The INI isoform of 5-HT2C was selected for crystallography, pharmacological and mutagenesis experiments.
Rational Design of Thermostabilizing Mutations
To increase the thermostability and homogeneity of the 5-HT2C, point mutations were rationally designed using a recently developed
tool for GPCR stabilization mutation predictions. The tool starts with the sequence and structural models of the target GPCR, and
explicitly evaluates all possible point mutations using four synergistic scoring models. These scoring models were derived using:
(i) knowledge about previously characterized stabilizing mutations transferable betweenGPCRs; (ii) variations in sequences between
closely related GPCRs; (iii) machine-learning algorithm trained on all knownmutations in GPCRs; and (iv) structure-based information
for residue interactions. A 3D homology model of human 5-HT2C was constructed and refined with ICM molecular modeling suite
(Abagyan and Totrov, 1994) using the X-ray structure of 5-HT2B (PDB: 4IB4) (Wacker et al., 2013) as a template. The best 40 candidate
point mutations predicted by the tool were selected for experimental validation. The candidates were analyzed for improvement of
the 5-HT2C monodispersity as evidenced by analytical size exclusion chromatography (aSEC) traces and thermal stability as evi-
denced by increase in Tm in the CPM assay (Alexandrov et al., 2008). Eight mutations were found to improve monodispersity and
thermostability by more than 2 degree, of which the mutation C360N7.45 was included into the engineered 5-HT2C construct.
Protein Engineering for Structure Determination
The sequence of the human 5-HT2C gene was synthesized by GenScript. The modified thermostabilized apocytochrome b562RIL
(BRIL) as a fusion partner was inserted into the receptor’s third intracellular loop (IL3) at L246 and M300 of the human 5-HT2C
gene, using overlapping PCR. The construct was further optimized by truncation of N-terminal residues 1-39 and C-terminal residues
393-458. The DN-5-HT2C-BRIL-DC DNA was subcloned into a modified pFastBac1 vector for expression in Spodoptera frugiperda
(Sf9) cells. The chimera sequence has a haemagglutinin (HA) signal sequence followed by a FLAG tag at theN terminus, a PreScission
protease site and a 103His tag at the C terminus. One rationally designed point mutation, C360N7.45 (Table S7), was engineered into
the 5-HT2C gene by standard QuickChange PCR.
Protein Expression
The Bac-to-Bac Baculovirus Expression System (Invitrogen) was used to generate high-titer recombinant baculovirus (> 109 viral
particles per ml). Recombinant baculovirus was produced by transfecting recombinant bacmids (2.5-5 mg) into Spodoptera
frugiperda (Sf9) cells (2.5 mL, density of 106 cells per mL) using 5 mL of X-tremeGENE HP DNA Transfection Reagent (Roche) and
Transfection Medium (Expression Systems). After 4 d of shaking at 27C, P0 viral stock (109 virus particles per mL) was harvested
as the supernatant of the cell suspension to produce high-titer viral stock. Viral titers were analyzed by flow cytometry on cells stained
with gp64-PE antibody (Expression Systems). 5-HT2C was expressed by infecting Sf9 cells at a cell density of 2-33 10
6 cells per ml
with P1 virus at MOI (multiplicity of infection) of 5. Cells were harvested by centrifugation of 48 hours post infection and stored
at 80C for future use.
Protein Purification
Thawed insect cell membranes were disrupted in a hypotonic buffer containing 10 mM MgCl2, 20 mM KCl, 10 mM HEPES (pH 7.5)
and EDTA-free complete protease inhibitor cocktail tablets (Roche). The isolated rawmembranes were extensively washed by twice
repeated centrifugation in the same hypotonic buffer. Subsequently, soluble and membrane associated proteins were removed in a
high osmotic buffer containing 10 mM MgCl2, 20 mM KCl, 1.0 M NaCl, 10 mM HEPES (pH 7.5) and EDTA-free complete protease
inhibitor cocktail tablets (three times). Purified membranes were flash-frozen in liquid nitrogen and stored at 80C for further use.
Purified membranes were thawed at room temperature and incubated in the presence of 50 mM ERG or RIT and protease inhibitor
cocktail at 4C for 2 h. The membranes were incubated with 1.0 mg/mL iodoacetamide (Sigma) for 30 min and were solubilized in the
buffer containing 50 mM HEPES (pH 7.5), 1% (w/v) n-dodecyl-beta-D-maltopyranoside (DDM, Anatrace), 0.2% (w/v) cholesterol
hemisuccinate (CHS, Sigma-Aldrich) and 150 mM NaCl, at 4C for 2.5 h. The solubilized 5-HT2C proteins in the supernatants were
isolated by high-speed centrifugation (Beckman), and then incubated at 4C overnight with TALON IMAC resin (Clontech),
800 mM NaCl and 20 mM imidazole as the final buffer concentration. The resin was washed with 10 column volumes of washing
buffer I containing 50 mM HEPES (pH 7.5), 0.1% (w/v) DDM, 0.02% (w/v) CHS, 800 mM NaCl, 10% (v/v) glycerol, 20 mM imidazole
and 50 mM ERG or RIT, and 6 column volumes of washing buffer II containing 50 mM HEPES (pH 7.5), 0.02% (w/v) DDM, 0.004% (w/v) 
CHS, 500 mM NaCl, 10% (v/v) glycerol and 50 mM ERG or RIT without imidazole. The protein was eluted using 4 column volumes of 
elution buffer containing 50 mM HEPES (pH 7.5), 0.02% (w/v) DDM, 0.004% (w/v) CHS, 500 mM NaCl, 10% (v/v) glycerol, 250 mM 
imidazole and 50 mM ERG or RIT. The 5-HT2C protein sample was concentrated to 30 mg/mL using a 100 kDa cutoff concentrator 
(Sartorius) for crystallization trials. The protein yield and monodispersity were measured by aSEC.
Lipidic Cubic Phase Crystallization
The purified 5-HT2C protein in complex with ERG or RIT was screened for crystallization in lipidic cubic phase (LCP) with mixed 
molten lipid (90% (w/v) monoolein and 10% (w/v) cholesterol) at a protein/lipid ratio of 2:3 (v/v) using a mechanical syringe mixer (Caf-
frey and Cherezov, 2009). LCP crystallization trials were set up using an NT8-LCP crystallization robot (Formulatrix). 96-well glass 
sandwich plates were incubated at 20C in an automatic incubator/imager (RockImager 1000, Formulatrix) and imaged. Crystals 
were obtained in 0.1 M sodium citrate pH 6.0, 80-120mM (NH4)2SO4, 25%–32% PEG400, and grew to full size around two weeks. 
The crystals were harvested using micromounts (MiTeGen) and flash-frozen in liquid nitrogen.
Data Collection and Structure Determination
X-ray diffraction data of 5-HT2C-ERG and 5-HT2C-RIT crystals were collected at beam line 41XU at SPring-8, Japan, using a Pilatus3 
6M detector, GM/CA at APS of Argonne National Lab, and X06SA beamline at the Swiss Light Source of the Paul Scherrer Institute, 
using Eiger 6M detector (X-ray wavelength 1.0000 Å ). The data collection strategy was designed based on rastering results as pre-
viously described (Cherezov et al., 2009). Diffraction images were indexed, integrated and scaled using XDS (Kabsch, 2010) and 
merged using SCALA (Collaborative Computational Project, Number 4, 1994). Initial phases were obtained by molecular replacement 
(MR) method with Phaser (McCoy et al., 2007) using the receptor and BRIL portions of 5-HT2B (PDB: 4IB4) as independent search 
models. In contrast to the 5-HT2C-ERG, only receptor portion was found in the 5-HT2C-RIT structure and partial BRIL was modeled 
during the refinement. Refinement was carried out with Phenix (Adams et al., 2010) and Buster (Smart et al., 2012) alternately followed 
by manual examination and adjustments of the refined structures in the program COOT (Emsley et al., 2010) with both 2jFoj-jFcj and 
jFoj-jFcj maps. In the final refined 2jFoj-jFcj maps, most of the 7TM structure and BRIL are ordered in the 5-HT2C-ERG structure while 
full receptor and around 50% of the fusion partner BRIL are modeled in the 5-HT2C-RIT structure.
Protein Stability Assays
Protein homogeneity was tested by aSEC using a 1260 Infinity HPLC system (Agilent). Protein thermostability was measured by a 
microscale fluorescent thermal stability assay as previously detailed (Alexandrov et al., 2008). For thermostability assay, CPM 
(N-([4-(7-diethylamino-4-methyl-3-coumarinyl) phenyl] maleimide) dye was dissolved in DMSO at 4 mg/ml as stock solution and 
diluted 1:20 in buffer (25 mM HEPES, pH 7.5, 500 mM NaCl, 5% (v/v) glycerol, 0.01% (w/v) DDM, 0.002% (w/v) CHS) before use. 
1 mL of diluted CPM dye was added to the same buffer with approximately 0.5–2 mg 5-HT2C receptor protein in a final volume of 
50 mL. The thermal denaturation assay was performed in a Rotorgene realtime PCR cycler (QIAGEN). The excitation wavelength 
was 365 nm and the emission wavelength was 460 nm. All assays were performed over a temperature range from 25C to 95C. 
The stability data were processed with GraphPad Prism 6.0.
ERG Binding Target Profiling
The class A GPCR ERG target profiling was performed using a manual site search in the GPCRdb (Isberg et al., 2016) searching all 
receptors of the class for specific amino acids in the positions determined to be important for ERG binding in our structure- and 
sequence-based analysis of the ERG binding site. Specifically, the requirements for amino acids were as follows: position 3.32 - short 
and negatively charged (SN), i.e., Asp; position 3.33 - intermediate length and hydrophobic (IH), i.e., Ala, Ile or Val; position 3.36 and 
5.42 - small and unbranched (SU), i.e., Ala, Cys, Gly or Ser; position 3.37 and 5.46 - very small or small and polar (VSP), i.e., Ala, Gly, 
Ser or Thr; position 6.51 and 6.52 - hydrophobic and maximum size of Phe (HF), i.e., Ala, Ile, Leu, Met, Phe or Val; position 209EL2 (in 
5-HT2C) - hydrophobic and aliphatic (HA), i.e., Ala, Ile, Leu, Met or Val. The search for high affinity ERG targets required all nine 
positions to match the aforementioned search criteria, while the search for low affinity ERG targets required Asp in position 3.32 
but allowed non-matching amino acids in two of the other eight positions.
ChEMBL Privileged Structure Search
All ligands with Ki < 1  mM on any class A GPCR was retrieved from the ChEMBL (Bento et al., 2014) database (release CHEMBL22, 
https://doi.org/10.6019/CHEMBL.database.22) and searched for compounds containing the 4-arylpiperidine using Instant JChem 
17.3.27.0, 2017, ChemAxon. The privileged structure was defined as a piperadine/piperazine ring connected to any heavy atom by a 
single/double bond, which is again connected to a six-membered aromatic ring. As the protonation is required, the nitrogen most 
distal from the aromatic ring cannot be part of an amine, sulfoneamide or be connected to any aromatic moiety. Furthermore, due to 
limited space in the pocket accommodating the privileged structure, position 2 and 3 on the aromatic ring should be unsub-stituted; 
substituents in position 4 and 5 are limited to non-cyclic moieties of only two heavy atoms.
Generation of 5-HT2C Mutant Constructs
Mutagenesis of 5-HT2C Flp-In 293 T-Rex and Tango constructs was performed using the Quikchange II XL site-directedmutagenesis
protocol, except using Primerstar Max (Takara/Fisher) as the DNA polymerase. After DpnI (New England Biolabs) digest of parental
DNA and transformation, positive colonies containing the mutation were selected using carbenicillin agar plates (Teknova). DNA was
prepped using Maxi prep kits (Origene), and sequenced using the Sanger method by Genewiz (South Plainfield, New Jersey, USA).
Membrane Preparation and Radioligand Binding
For membrane preparation, HEKT (ATCC) cells (approximately 63 106 cells/15-cm dish) were transfected with 15 mg DNA per 15 cm
dish of 5-HT2C wild-type or mutant DNA (Table S7) using the calcium phosphate DNA precipitation method (Jordan et al., 1996). After
48 h transfection in DMEM containing 10% dialyzed FBS, cells were lysed using hypotonic lysis buffer (1 mM HEPES, 2 mM EDTA,
pH 7.4) for 10min, resuspended and centrifuged at 30,0003 g. After decanting of lysis buffer, membraneswere resuspended in bind-
ing buffer (50 mM Tris, 10 mM MgCl2, 0.1 mM EDTA, pH 7.4) and centrifuged at 13,000 3 g in pre-chilled 1.7 mL centrifuge tubes.
Buffer was decanted and membrane pellets were stored at 80C until use.
Radioligand binding assays utilized [3H]-Mesulergine (Perkin Elmer; Specific Activity = 84.7 Ci/mmol) at concentrations ranging
from 0.7-1.3 nM, unlabeled ligand competitor at concentrations ranging from 100 mM to 1 pM, andmembranes resuspended in bind-
ing buffer (50 mM Tris, 10 mM MgCl2, 0.1 mM EDTA, 0.1% BSA, 0.01% ascorbic acid, pH 7.4). Binding assays were incubated at
37C for 4 h and assays were terminated by vacuum filtration using a 96-well Filtermate harvester onto 0.3% polyethyleneimine
pre-soaked 96-well filter mats A (Perkin Elmer). Filters were washed three times using cold wash buffer (50 mMTris, pH 7.4) and scin-
tillation cocktail (Meltilex) was melted onto dried filters. Radioactivity displacement was measured using a Wallac Trilux Microbeta
counter (Perkin Elmer). Counts per minute (CPM) were plotted as a function of unlabeled ligand concentration and the Ki was calcu-
lated using the One-site-Fit Ki using Graphpad Prism 5.0. Data were normalized to the top (100%, no competitor) and bottom (0%,
10 mM 5-HT) to represent percent displacement.
For radioligand binding assays at all other receptors, procedures were similar as described except for the radioligand used and
membrane sources. For a list of these binding assays refer to detailed procedures at https://pdspdb.unc.edu/pdspWeb/ for the
National Institute of Mental Health Psychoactive Drug Screening Program (NIMH PDSP) (Besnard et al., 2012).
Test for RIT Selectivity Mutations
The RIT selectivity 5-HT2C mutants were generated using Quikchange II XL site-directed mutagenesis (Stratagene, San Diego, CA)
and oligonucleotides (TAG Copenhagen, Copenhagen, Denmark) (Table S7). After DpnI (New England Biolabs) digest of parental
DNA and transformation, positive colonies containing the mutation were selected using ampicillin agar plates. DNA was prepped
using aMaxi prep kit (QIAGEN, Hilden, Germany), and the integrity of and the absence of unwantedmutations in all cDNAs generated
by PCR were verified by DNA sequencing (Eurofins MWG Operon, Ebersberg, Germany).
The tsA201 cells were grown andmaintained in culture medium [Dulbecco’s Modified Eagle Medium supplemented with 10% fetal
bovine serum, penicillin (100 U/mL) and streptomycin (100 mg/mL), all from Invitrogen] in a humidified atmosphere at 37C and 5%
CO2. The cells were transiently transfected with wild-type and mutant h5-HT2C-pcDNA3.1 constructs using PolyFect
 (QIAGEN)
according to the manufacturer’s instructions. The culture medium was changed 16-20 h after transfection and membranes were
harvested 36-48 h after transfection. The cells were scraped into harvest buffer (50 mM Tris-HCl, pH adjusted to 7.4 with NaOH),
homogenized using an Ultra-Turrax for 10 s and centrifuged for 20 min at 50,0003 g. The resulting pellets were resuspended in fresh
harvest buffer, homogenized and centrifuged at 50,0003 g for another 20 min, after which the pellet was stored at 80C until use.
In the saturation binding experiments, the membranes were incubated with various concentrations (nine ranging from 0.03 nM to
10 nM) of [3H]-mesulergine (Perkin-Elmer) in the absence (total binding) or the presence of 30 mM mianserin (non-specific binding)
and, in competition binding experiments, the membranes were incubated with a fixed [3H]-mesulergine concentration (0.5 nM or
2 nM, depending on the Kd value displayed by [
3H]-mesulergine at the specific receptor) and various concentrations of the test com-
pounds (all from Tocris Cookson) in assay buffer (50 mM Tris-HCl, 10 mM MgCl2, 0.1 M EDTA, 0.1% fatty acid-free bovine serum
albumin and 0.01% ascorbic acid, pH adjusted to 7.4 with NaOH, freshly prepared each day) in a total volume of 300 mL. The
experiments were performed in duplicate and the amount of membranes used was adjusted so that the bound/free ratios of [3H]-me-
sulergine were10% or lower in all reactions. The mixtures were incubated for 2 h at 37C and harvested into UniFilter 96-well GF/C
plates using a FilterMate Harvester (PerkinElmer), washed with 2 mL/well wash buffer (10 mM Tris-HCl, 0.9% w/v NaCl, pH 7.4) and
dried for at least 1 h at 50C. 30 mLMicroScint0 (PerkinElmer) was added to each well in the filter, the plates were incubated for 1 h at
room temperature, and the bound radioactivity were determined on a TopCount NXT scintillation counter. All data analysis was per-
formed in GraphPad Prism 7.0b (GraphPad Software).
Phosphoinositide Hydrolysis (PI) Assay
Stable cell lines were generated in Flp-In 293 T-Rex cells expressing either 5-HT2C wild-type or indicated mutants (Table S7). Phos-
phoinositide hydrolysis (PI) assays were performed using the scintillation proximity assay previously described (Bourdon et al., 2006;
Huang et al., 2009). Briefly, tetracycline-induced cells (50-75,000 cells/well) were plated in inositol and serum-free DMEM (Caisson
Labs) containing 1mCi/well of [3H]-myo-inositol (Perkin Elmer) onto 96-well white plates. After 16-20 h, media was decanted, cells
were washed and wells were replaced with 200 mL of inositol and serum-free DMEM. Drugs were diluted in drug buffer (20 mM
HEPES, 1X HBSS, 0.1% BSA, 0.01% ascorbic acid, pH 7.4) and 50 mL (5x) was applied to cells in concentrations ranging from 100 mM 
to 1 pM. Plates were incubated for either 60-120 min at 37C and 5% CO2. Lithium chloride (15 mM final concentration) was added to 
cells 15 min before lysis for IP capture and cells were lysed with 50 mM formic acid. Next day, 10 mL of lysate was added to 75 mL of  
0.2 mg/well of RNA binding yttrium silicate scintillation beads (Perkin Elmer) in 96-well flexible, clear microplates. Plates were shaken 
for 1 h and centrifuged at 500 3 g briefly for 1 min before reading on a Wallac MicroBeta Trilux plate reader (Perkin Elmer) measuring 
counts per minute (CPM). Data were analyzed using log (agonist) versus response (CPM) using Graphpad Prism 5.0. Data were 
normalized to percent 5-HT response, which was present in every experiment.
Tango Arrestin Recruitment Assay
The 5-HT2C arrestin recruitment assays were performed as previously described (Cheng et al., 2016; Kroeze et al., 2015). Briefly, 
HTLA cells expressing the TEV fused-b-arrestin2 were transfected with 15 mg 5-HT2C wild-type or mutant DNA per 15-cm dish in 
10% dialyzed FBS DMEM. Next day, cells were plated into white 384-well plates at a density of 15,000 cells per well in 40 mL of  
1% dialyzed FBS DMEM. After 6 h cells were stimulated with drugs ranging in concentration from 100 mM to 1 pM diluted in drug 
buffer (20 mM HEPES, 1X HBSS, 0.1% BSA, 0.01% ascorbic acid, pH 7.4) at a 5 3 concentration. After 20-22 h of incubation at 
37C and 5% CO2 media was decanted and 20 mL of BriteGlo (Promega, after 1:20 dilution) was added per well. After 20 min, plates 
were read on a Wallac MicroBeta Trilux (Perkin Elmer) at 1 s per well. Luminescence counts per second (LCPS) were plotted as a 
function of drug concentration and analyzed using log (agonist) versus response (LCPS) using Graphpad Prism 5.0. Data were 
normalized to percent 5-HT response, which was present in every experiment.
GPCRome Screening
Agonist activity at human GPCRome was determined as outlined previously (Kroeze et al., 2015) with modifications as indicated 
below. Briefly, HTLA cells were plated in poly-lysine coated 384-well white clear bottom plates in DMEM supplemented with 10%
FBS (10,000 cells in 40 mL per well). After overnight incubation, cells received additional 10 mL/well of fresh DMEM supplemented 
with 50% FBS and transfected with receptor DNA (15 ng/well) for 24 h. Medium was removed and replaced with 40 mL/well of 
DMEM supplemented with 1% dialyzed FBS followed by 10 mL/well drug solution at 5 3 of a final concentration (1, 3, and 
10 mM). Medium with 1% dialyzed FBS served as basal for each receptor. After overnight incubation (18 h), medium and drug so-
lutions were removed and 20 mL/well of BrightGlo reagents (Promega) were added. Luminescence (Relative Luminescence Unit, 
RLU) was read on a luminescence reader, SpectraMax L (Molecular Devices), after 20 min incubation at room temperature. The assay 
was designed in this way so that 40 receptors were tested in each 384-well plate; each receptor had 4 replicate wells with testing drug 
and 4 replicate wells with vehicle control. Dopamine receptor D2 serves as an assay control-16 replicate wells with 0.1 mM Quinpirole 
and 16 replicate wells with vehicle control. An additional 32 wells served as background control. Basal counts ranged from 70 –
120000 and were arranged in assay plates to avoid/minimize cross-talk, as described previously (Kroeze et al., 2015). Each 
GPCRome screening needs a total of 8x 384-well plates. Results were presented in the form of fold over basal for each receptor 
and plotted in the GraphPad Prism.
Docking of Lorcaserin
All molecular modeling calculations mentioned in this section were performed using modules (Maestro, Ligprep, Protein Preparation 
Wizard and Glide) in the Small-Molecule Drug Discovery Suite 2017-2, Schrö dinger, LLC, New York, NY, 2017. Lorcaserin was built in 
Maestro using the 2D-sketcher and the 3D-structure was generated using LigPrep with default settings. The 5-HT2C-ERG structure 
was preprocessed and optimized with default settings in the Protein Preparation Wizard and a docking grid was calculated with Glide 
defining the binding site by selecting ERG and setting the ligand diameter midpoint box to 12 Å on all three axes – otherwise default 
settings. Finally, lorcaserin was docked into the calculated receptor grid using the XP scoring function, a scaling factor of 0.7 and 
partial charge cutoff of 0.2 to compensate for the lack of the forcefield to correctly take halogen bonds into account. Additionally, 
five output poses were specified, post-docking minimization was disabled. The best ranking of only two suggested similar binding 
modes were selected.
QUANTIFICATION AND STATISTICAL ANALYSES
Dose-Response and Binding Affinity Calculations
Dose-response data and radioligand displacement data were analyzed using Graphpad Prism 5.0. Dose-response data were fit using 
log (agonist) versus response function, which constrains the hill slope to 1. Estimates of EMAX and EC50 were fit and data were normal-
ized to a reference ligand (for 5-HT2C reference was 5-HT) and averaged across independent experiments using Graphpad Prism 5.0. 
Specific [3H]-mesulergine binding and Kd values of the radioligand at the various receptors were determined based on fitting of the 
saturation binding data to a one-site total and non-specific equation and Ki values were calculated based on the IC50 values extracted 
from concentration-inhibition curves derived from the competition binding data using the Cheng-Prusoff equation in Graphpad 
Prism 5.0.
Test for RIT Selectivity Mutations
For Kd and pKi analysis, we have one dependent variable (Kd or pKi), and the independent variable(s) consists of several categorical
independent groups. For Kd we are comparing the [
3H]-mesulergine binding of each mutant against the WT receptor (one indepen-
dent group). For pKi, we are comparing each compound at eachmutant against that compound at theWT receptor (two independent
groups). Since Ki is determined from a logarithmic scale of compound concentration, all further calculations are done with pKi values.
Our data contained no significant outliers, as determined using the ROUT analysis fromGraphPad Prismwith the false discovery rate
set to 1%. Our sample size is too small to meaningfully test for normal distribution, but all Kd and pKi values do pass the Shapiro-Wilk
normality test with a = 0.05, and a normal distribution is assumed for all groups. The number of independent repeats is similar
between groups and/or the variance is similar between groups. Not all mutants were tested on each assay day. We have thus elected
to use a non-paired one-way ANOVA for the Kd comparison, and a non-paired two-way ANOVA for the pKi comparison. Since we, in
both Kd and pKi comparisons, are comparing a control (WT) mean with other means, we have used the Dunnetts post-test for both to
avoid the artifact of falsely wide confidence intervals often resulting from using Tukey’s post-test for many-to-one comparisons.
DATA AND SOFTWARE AVAILABILITY
Data Resources
The accession numbers for the coordinates and structure factors of 5-HT2C-ERG and 5-HT2C-RIT are PDB: 6BQG and PDB: 6BQH,
respectively.
Figure S1. Stability Assay of 5-HT2C Mutant, Ligands, and Crystal Images, Related to Figure 1
(A) Analytical size exclusion chromatography (aSEC). NoMut-APO: N/C-terminal truncated and BRIL inserted into the IL3 construct without mutation and without
ligand (gray); C360N7.45-APO: C360N7.45 mutated in the engineered construct without ligand (purple); C360N7.45-RIT: C360N7.45-APO with RIT (green);
C360N7.45-ERG: C360N7.45-APO with ERG (orange).
(B) CPM thermostability ramping assay of 5-HT2C at different forms of protein as tested.
(C) Crystal images of 5-HT2C bound to ERG and to RIT. The length of the reference white band is 80 mm.
Figure S2. Structural Alignment of 5-HT2C-ERG and 5-HT2C-RIT with b2AR in the Active State (PDB: 3SN6) and Inactive State (PDB: 3NY8) and
Differences in the Relative Location at the Ends of Intracellular Helices in Four Serotonin Receptors Crystal Structures, Related to Figure 1
(A) 5-HT2C-ERG, orange; 5-HT2C-RIT, green; active state b2AR, magenta; inactive state of b2AR, gray. (Left panel) Intracellular view. (Right panel) Extracel-
lular view.
(legend continued on next page)
(B) The conformation similarities of the trigger motifs PIF, DRY, and NPxxY in 5-HT2C-ERG versus active state b2AR and 5-HT2C-RIT versus inactive state of b2AR
structures, respectively.
(C) Four crystal structures (5-HT2C-RIT: green, 5-HT2C-ERG: orange, 5-HT1B-ERG: light blue (PDB: 4IAR) and 5-HT2B-ERG: yellow (PDB: 4IB4)) represented as
cartoons and viewed from the intracellular side. Representative distances between Ca atoms of V78
1.57, I1483.46 and L3136.37 (selected to be at the same helical
height) are shown as dashed lines with labeled distances in Å. The 5-HT2C structures with ERG and RIT show the largest and smallest inter-helical distances in the
intracellular ends, respectively.
(D) A schematic illustrating the differences in relative positions of the TM helices defined by RMSDs between ERG-bound 5-HT1B,2B,2C and RIT-bound 5-HT2C
structural conformations.
Figure S3. Pharmacological Profile of ERG and RIT at 5-HT2C, Related to Figure 3
(A andB) ERG shows potent agonism andRIT shows inverse agonist activity for both (A) Gaq-dependent and (B) Gaq-independent b-arrestin2 recruitment to the 5-
HT2C. Data represent mean ± SEM from at least four independent experiments performed in triplicate.
Figure S4. Analysis of the Function of ERG on a Panel of Aminergic Receptors, Related to Figure 4
Analysis of the function of ERG on a panel of aminergic receptors shows the varied profile of ERG as agonist, inverse agonist, or antagonist at select receptors.
The functional profile includes either G protein-dependent activity and b-arrestin2 recruitment or both for adrenergic, dopamine, and serotonin receptors. All
receptors tested are human wild-type aminergic receptors. Data performed in triplicate and represent mean ± SEM from at least three independent experiments.
Figure S5. GPCRome Screening Results, Related to Figure 4
Screening of ERG across the GPCRome (at 320 receptors) using the PRESTO-Tango platform with ergotamine present at 1mM, 3 mM, and 10 mM concentrations.
Additional details on method, basal activities, and plate arrangement can be found in the methods.
Figure S6. Binding Mode and Mechanism of Selectivity for Lorcaserin, Related to Figure 6
Docking binding mode of lorcaserin (white sticks) in the 5-HT2C-ERG structure (light blue cartoon and orange sticks) showing similar location of the protonated
amines and aromatic moieties. In addition, the binding pose of lorcaserin is comparable to RIT in the 5-HT2C-RIT structure (green cartoon and sticks in the inset),
the chlorine of lorcaserin is in close proximity to the Ca atom of the 5-HT2 group-unique residue, G218
5.42, and can explain the reported binding selectivity of
lorcaserin for these receptor subtypes (Thomsen et al., 2008). The figure was prepared using The PyMOL Molecular Graphics System, Version 1.8 Schrö-
dinger, LLC.
